Sign in Create account

Emmessar Biotech & Nutrition Ltd.

Chemicals · Chemicals & Petrochemicals

BSE: 524768
₹23.67
▼ -0.07 (-0.29%)
Oct. 5, 2026 · BSE · bse_bhavcopy
Quality
64/100
Moderate
Valuation
71/100
Undervalued
Momentum
48/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹12 Cr
PE (TTM)
29.2
Industry median 24.5 (189 companies)
Price to Book
1.5
PEG (TTM)
0.9
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-42.8
Free Cash Flow
₹-0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
106.25%
as of March 31, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
-25.90%
as of March 31, 2026
Industry median 13.45% (212 companies)
Operating Revenue Growth (TTM)
-39.28%
as of March 31, 2026
Industry median 7.93% (209 companies)
Profit Growth (YoY)
-59.14%
as of Sept. 30, 2025
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
-3.13%
as of March 31, 2026
Industry median 17.49% (205 companies)
Current Ratio
20.28
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
242.67
as of March 31, 2026
Industry median 8.97 (221 companies)
Net Margin
123.91%
as of Sept. 30, 2025
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
86.67%
as of March 31, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
156.98%
as of March 31, 2026
Industry median 9.75% (219 companies)
Return on Assets
5.19%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
6.37%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
6.10%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (6.1%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.3%
Low 22.5100 · High 23.9800
1W return
4.5%
Low 22.0100 · High 24.5000
1M return
-0.4%
Low 22.0100 · High 25.0000
52W return
-47.5%
Low 22.0100 · High 27.7000
Lifetime High ₹55.6500 (July 29, 2021)
Lifetime Low ₹2.7000 (Jan. 10, 2014)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish1
Bearish5
5D
23.6
10D
23.7
20D
24.1
50D
27.1
100D
29.8
200D
31.4

Delivery and volume

Day avg. delivery
82.3%
Week avg. delivery
91.1%
Month avg. delivery
85.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

23.39
Pivot
First resistance24.26
Second resistance24.86
Third resistance25.73
First support22.79
Second support21.92
Third support21.32
Day RSI44.0
Day MFI28.1
Day MACD-0.90
Day MACD signal-1.17

Beta

1M-0.46
3M-0.80
1Y-0.80
3Y0.67

Price change analysis

↓ -0.4%
Over 1 Month
LowHigh
22.0125.00
↓ -47.5%
Over 3 Months
LowHigh
22.0127.70
↓ -47.5%
Over 6 Months
LowHigh
22.0127.70
↓ -47.5%
Over 1 Year
LowHigh
22.0127.70
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 29.2 (own history: 20.2–102.5)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (March 31, 2026)
₹0 Cr
Net profit (March 31, 2026)
₹— Cr
Basic EPS (March 31, 2026)
₹0.0100

Ranks #204 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter59.53%
  • Mutual funds0.05%
  • Other DII0.15%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 59.53% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.05% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 27 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
27 Mar 2026 PRATIBHA DINESH SHAH Bulk Sell 43,337 24.6600 BSE
27 Mar 2026 AIMS FINANCIAL VENTURES Bulk Buy 45,000 24.7200 BSE
29 Jul 2025 QUANTSEYE AI PRIVATE LIMITED Bulk Sell 25,333 29.2900 BSE
13 Dec 2024 SHRENIK DINESH SHAH Bulk Sell 26,000 43.6000 BSE
13 Dec 2024 PRATIBHA DINESH SHAH Bulk Buy 38,181 43.6000 BSE
12 Nov 2024 AIMS FINANCIAL VENTURES Bulk Sell 25,991 51.5000 BSE
12 Nov 2024 SHRENIK DINESH SHAH Bulk Buy 26,000 51.5000 BSE
16 Oct 2024 PRACHI PRAKASH RAKTATE Bulk Sell 4,589 62.8500 BSE
16 Oct 2024 AIMS FINANCIAL VENTURES Bulk Buy 25,986 61.4200 BSE
16 Oct 2024 PRACHI PRAKASH RAKTATE Bulk Buy 32,264 63.4400 BSE

All bulk and block deals →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Emmessar Chemical Industries Ltd. to Emmessar Biotech & Nutrition Ltd.

All corporate actions →

Corporate Announcements

All 7 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
2 Oct 2026 Company Update Emmessar Biotech & Nutrition Ltd - 524768 - Newapaper Add For Relodgment Of Shares
29 Sep 2026 Insider Trading / SAST Emmessar Biotech & Nutrition Ltd - 524768 - Closure of Trading Window
29 Sep 2026 AGM/EGM Emmessar Biotech & Nutrition Ltd - 524768 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 AGM/EGM Emmessar Biotech & Nutrition Ltd - 524768 - Scutinizers Report
5 Sep 2026 Company Update Emmessar Biotech & Nutrition Ltd - 524768 - Newspaper Add
4 Sep 2026 AGM/EGM Emmessar Biotech & Nutrition Ltd - 524768 - Notice Of The 34Th Annnual General Meeting Of The Company To Be Held On September 29, 2026
4 Sep 2026 Others Emmessar Biotech & Nutrition Ltd - 524768 - Reg. 34 (1) Annual Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (123.9%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (242.7x)

Weaknesses

  • Low Return on Equity (6.1%)
  • Declining revenue YoY (-3.1%)
  • Declining profit YoY (-59.1%)

Opportunities

  • PEG below 1 (0.89) -- earnings growth outpacing its own valuation

Threats

  • Down 47.5% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Emmessar Biotech & Nutrition Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.